Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants

Yoshitomo Morinaga, Hideki Tani, Yasushi Terasaki, Satoshi Nomura, Hitoshi Kawasuji, Takahisa Shimada, Emiko Igarashi, Yumiko Saga, Yoshihiro Yoshida, Rei Yasukochi, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Takashi Fujimura, Yoichi Ishida, Kazunori Oishi, Yoshihiro Yamamoto
doi: https://doi.org/10.1101/2021.05.25.21257828

Data Availability

All available data are in the figures and Tables including supplementary data.

Back to top
Posted May 27, 2021.
Download PDF
Data/Code
Email
Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants
Yoshitomo Morinaga, Hideki Tani, Yasushi Terasaki, Satoshi Nomura, Hitoshi Kawasuji, Takahisa Shimada, Emiko Igarashi, Yumiko Saga, Yoshihiro Yoshida, Rei Yasukochi, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Takashi Fujimura, Yoichi Ishida, Kazunori Oishi, Yoshihiro Yamamoto
medRxiv 2021.05.25.21257828; doi: https://doi.org/10.1101/2021.05.25.21257828
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area